Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron.
Open Forum Infect Dis
; 10(6): ofad279, 2023 Jun.
Article
en En
| MEDLINE
| ID: mdl-37351456
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Open Forum Infect Dis
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos